Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial

Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial

Abstract Endometrial cancers are characterized by frequent alterations in the PI3K-AKT-mTor, IGF1 and DNA repair signaling pathways. Concomitant inhibition of these pathways was warranted. ENDOLA phase I/II trial (NCT02755844) was designed to assess the safety/efficacy of the triplet combination of...

Full description

Bibliographic Details
Main Authors: Max Piffoux, Alexandra Leary, Philippe Follana, Cyril Abdeddaim, Florence Joly, Sylvie Bin, Maxime Bonjour, Anais Boulai, Celine Callens, Laurent Villeneuve, Marine Alexandre, Verane Schwiertz, Gilles Freyer, Manuel Rodrigues, Benoit You
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56914-7

Internet

https://doi.org/10.1038/s41467-025-56914-7

Similar Items